FIRE Funds Income Target ETF FIRI 深 沪
等待开盘 12-18 09:30:00 美东时间
18.9449
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 18.9449
- 总市值 123.14万
- 52周最高 19.115
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 17.6612
- 委 比 0.00%
- 总股本 6.50万
- 历史最高 18.1637
- 量 比 0
- 振 幅 0.00%
- 历史最低 17.7417
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
12-17 02:17
Oncolytics Biotech Announces Clinical And Translational Findings Supporting Development Of Pelareorep In Second-Line mCRC, Specifically In Patients With KRAS- MSS Disease
33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11%Translational analysis shows pelareorep enhances KRAS-mutant–specific T-cell activity,
12-16 22:06
Akari Therapeutics Reports Its AKTX-101 Shows Potent Preclinical Activity Against K-Ras G12V Pancreatic Cancer Cells
Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival
12-09 21:41
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?
Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart.
10-24 15:05
Inhibrx Biosciences To Webcast ChonDRAgon Study Results For Ozekibart In Chondrosarcoma On October 23
– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT –SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical
10-23 04:02
Merus Reports Interim Phase 2 Results for Petosemtamab in Metastatic Colorectal Cancer
Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and
10-14 19:34
Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant setting Trial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE
09-29 20:19
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announc...
09-16 19:00
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Break...
09-08 21:30
